The drug failed in this DMD trial. As J.G. said, we don't want to throw the 'baby out with the bath water' until we do further research on the other indications for ATL1102, but at the same time, they are looking for other opportunities.
More news to come in the weeks/month ahead following this webinar on where the Company is heading - hopefully, they get the votes come March 4th and we can get down to business and clear the air in the process!
GLTAH
.
Ann: Webinar Presentation - Phase IIb study of avicursen, page-7
Add to My Watchlist
What is My Watchlist?
